Antimicrobial Agents Practice Questions

Q: Which one of the following groups of drugs is ineffective against gram positive bacteria?

Monobactams. Monobactams - **Monobactams**, such as **aztreonam**, have a narrow spectrum of activity primarily targeting aerobic **Gram-negative bacteria** [1]. - They lack significant activity against **Gram-positive organisms** and **anaerobes** due to differences in cell wall structure and penicillin-binding proteins (PBPs) [1]. *Glycopeptides* - **Glycopeptides**, like **vancomycin**, are highly effective against a wide range of **Gram-positive bacteria**, including **MRSA** (methicillin-resistant *Staphylococcus aureus*) [3]. - They inhibit cell wall synthesis by binding to the D-Ala-D-Ala precursor, which is crucial for **Gram-positive cell wall integrity**. *Fluoroquinolones* - **Fluoroquinolones** are broad-spectrum antibiotics with activity against both **Gram-positive** and **Gram-negative bacteria** [4]. - While some newer agents (*e.g., levofloxacin, moxifloxacin*) have enhanced **Gram-positive coverage**, older agents (e.g., **ciprofloxacin**) are less potent against Gram-positives [4]. *First generation cephalosporins* - **First-generation cephalosporins** (e.g., **cefazolin**, **cephalexin**) exhibit good activity against many **Gram-positive bacteria**, including **staphylococci** and **streptococci** [2]. - They are commonly used for infections caused by **Gram-positive organisms** and as surgical prophylaxis [2].

Q: For the treatment of kala-azar, the daily dose of miltefosine in a 3-year-old child who weighs 15 kg is

40 mg. ***40 mg*** - Miltefosine dosage for children weighing 12 to 29 kg (including a 15 kg child) is typically **2.5 mg/kg body weight per day orally**. - For a 15 kg child, this translates to 2.5 mg/kg * 15 kg = **37.5 mg**, which is rounded to **40 mg** for practical dosing since miltefosine capsules come in 10 mg or 50 mg sizes. *20 mg* - This dose is lower than the recommended **2.5 mg/kg/day** for a 15 kg child, which would be 37.5 mg. - An underdose of miltefosine could lead to **treatment failure** and the development of drug resistance. *10 mg* - This dose is significantly lower than the recommended therapeutic dose for a 15 kg child, which requires approximately **37.5 mg daily**. - Such a low dose would be **ineffective** in treating kala-azar, risking worsening disease. *30 mg* - While closer than 10 mg or 20 mg, 30 mg is still below the calculated **37.5 mg/day** for a 15 kg child. - An insufficient dose may compromise the efficacy of treatment and lead to **suboptimal parasitic clearance**.

Q: Which of the following statements is true about antibiotic therapy?

It has its greatest effect on multiplying organisms. ***It has its greatest effect on multiplying organisms*** - Most **antibiotics** target processes essential for bacterial growth and replication, such as cell wall synthesis, protein synthesis, or DNA replication. - Therefore, their efficacy is highest against **actively multiplying bacteria**, as these processes are most vulnerable during periods of rapid growth. *It enhances the intracellular killing of organisms by phagocytes* - Antibiotics primarily act directly on bacteria, either **killing them (bactericidal)** or inhibiting their growth (bacteriostatic), rather than directly augmenting host immune cell functions like intracellular killing by phagocytes. - While antibiotics reduce the bacterial load, which aids phagocytosis, they do not directly enhance the phagocyte's intrinsic killing mechanisms. *It facilitates killing of organisms by activation of complements* - The **complement system** is part of the innate immune response and is activated by antibodies or microbial surface components; antibiotics do not directly activate this system. - Antibiotic action is independent of complement activation, although a reduced bacterial load can indirectly influence the overall immune response. *It enhances the uptake of organisms by phagocytes* - Enhancing the uptake of organisms by phagocytes (opsonization) is primarily mediated by host immune components such as **antibodies** and **complement proteins**, which coat bacteria to facilitate recognition. - Antibiotics do not directly opsonize bacteria or enhance phagocytic uptake; their role is to inhibit or kill bacteria directly.

Q: Consider the following drugs : 1. Rifampicin 2. Dapsone 3. Clofazimine 4. Minocycline Which of the above drugs are used in the standard treatment of pauci-bacillary leprosy in adults?

1 and 2 only. ***1 and 2 only*** - The **WHO standard treatment regimen** for **pauci-bacillary leprosy** in adults consists of only two drugs: **Rifampicin** and **Dapsone** [1]. - **Rifampicin 600 mg** is administered once monthly under supervision for 6 months, while **Dapsone 100 mg** is given daily for 6 months [3]. - This regimen is sufficient for PB leprosy, which has fewer bacilli and 1-5 skin lesions with no nerve involvement or only one nerve trunk involved [1], [2]. *1, 2 and 3* - This combination includes **Clofazimine**, which is part of the **multi-bacillary (MB) leprosy** regimen, not pauci-bacillary [2], [3]. - MB leprosy requires triple therapy (Rifampicin + Dapsone + Clofazimine) for 12 months due to higher bacterial load and more extensive disease. - Pauci-bacillary leprosy has a lower bacterial load and requires only a 6-month two-drug regimen [1]. *1 and 4* - **Minocycline** is used in **alternative regimens** for leprosy, particularly for patients with drug intolerance or in single-lesion PB leprosy (ROM regimen). - It is **not part of the standard first-line WHO treatment** for pauci-bacillary leprosy in adults. - The standard PB regimen requires **Rifampicin plus Dapsone**, not Rifampicin plus Minocycline. *2, 3 and 4* - This option misses **Rifampicin**, which is the **most crucial bactericidal drug** for all forms of leprosy (both PB and MB) [3]. - **Clofazimine** and **Minocycline** are not part of the standard PB leprosy regimen—Clofazimine is reserved for MB leprosy, and Minocycline is used only in alternative regimens. - Without Rifampicin, the treatment would be inadequate and risk development of drug resistance [3].

Q: In a case of paucibacillary leprosy, treatment is considered adequate if the patient has received the six monthly doses of combined therapy within:

9 months. ***9 months*** - For **paucibacillary (PB) leprosy**, the standard multi-drug therapy (MDT) regimen consists of six monthly doses of **rifampicin** and **dapsone**. - According to **WHO guidelines**, this six-dose regimen should be completed within a maximum period of **9 months** to ensure effective treatment and minimize drug resistance. - This timeframe allows for occasional missed doses while maintaining treatment efficacy. *12 months* - This duration is used for **multibacillary (MB) leprosy**, which requires 12 doses within 18 months. - For paucibacillary leprosy, 12 months is considered too long and may lead to suboptimal treatment outcomes. *6 months* - Completing all six doses within 6 months would mean no missed doses, which is theoretically possible. - However, this timeframe is too strict and does not account for real-world scenarios where patients might miss appointments or doses. - The WHO guideline of 9 months provides appropriate flexibility. *15 months* - Extending the treatment completion period to 15 months for PB leprosy is considered too long. - A prolonged treatment duration can increase the risk of **drug resistance** and may lead to poor compliance, as patients might discontinue treatment early. - This duration far exceeds WHO recommendations for paucibacillary leprosy.

Q: Which of the following drugs should be avoided in the first-line ART regimens because of its well recognized metabolic toxicities ?

Stavudine (d4T). ***Stavudine (d4T)*** - **Stavudine** is a **nucleoside reverse transcriptase inhibitor (NRTI)** that is well-known for its significant **metabolic toxicities**, including **lipoatrophy**, peripheral neuropathy, and lactic acidosis [1]. - Due to these severe side effects, it is no longer recommended for first-line ART regimens and its use is generally avoided. *Tenofovir (TDF)* - While Tenofovir (TDF) can cause **renal toxicity** and **bone mineral density loss** [2], it is generally considered a safer option than stavudine regarding severe metabolic toxicities like lipoatrophy. - TDF is commonly used in first-line ART regimens, often in combination with other drugs. *Zidovudine (AZT)* - **Zidovudine** is associated with side effects such as **bone marrow suppression** (leading to anemia and neutropenia), myopathy, and gastrointestinal upset, but not typically the severe metabolic toxicities seen with stavudine. - It is still used in some ART regimens, particularly for prevention of mother-to-child transmission. *Lamivudine (3TC)* - **Lamivudine** is generally well-tolerated with a favorable side effect profile, primarily mild gastrointestinal symptoms, and is rarely associated with significant metabolic toxicities. - It is a cornerstone drug in many first-line ART regimens due to its efficacy and safety.

Q: All of the following drugs are effective for treatment of hookworm infection in single dose EXCEPT:

Piperazine. ***Piperazine*** - **Piperazine** is primarily effective against **Ascaris lumbricoides** and **Enterobius vermicularis**, acting as a depolarizing neuromuscular blocker. - It is **not effective** against hookworm infections and is therefore unsuitable for treating the human reservoir of hookworms. *Albendazole* - **Albendazole** is a broad-spectrum anthelminthic highly effective against hookworm infections, including **Necator americanus** and **Ancylostoma duodenale**. - A **single dose** is often sufficient due to its effectiveness in eliminating adult worms and reducing egg excretion. *Levamisole* - **Levamisole** is an anthelminthic that can be effective against hookworm species, working as a **ganglionic stimulant** causing paralysis of the worms. - A **single dose** regimen is typically adequate for hookworm treatment. *Pyrantel* - **Pyrantel pamoate** is effective against hookworms by causing **neuromuscular blockade**, leading to expulsion of the worms. - It is often given as a **single dose** for effective treatment of hookworm infections.

Q: The drug of choice for chemoprophylaxis to health care personnel and close contacts of suspected or confirmed case of pandemic influenza A (H1N1) is:

Oseltamivir. ***Oseltamivir*** - **Oseltamivir** is the recommended drug for chemoprophylaxis against pandemic influenza A (H1N1) for healthcare personnel and close contacts [1, 2]. - This recommendation is based on its effectiveness against the **neuraminidase** of the H1N1 virus, preventing viral release and spread. *Ribavirin* - **Ribavirin** is an antiviral agent used for conditions like chronic hepatitis C and RSV, but it is not recommended for influenza chemoprophylaxis. - Its mechanism of action and efficacy profile do not make it a primary choice for preventing H1N1 infection. *Amantadine* - **Amantadine** targets the M2 ion channel of influenza A viruses, but many H1N1 strains, including the pandemic strain, developed **resistance** to this drug [1]. - Due to widespread resistance, **amantadine** and rimantadine are no longer recommended for routine influenza treatment or prophylaxis [1]. *Zanamivir* - **Zanamivir** is another **neuraminidase inhibitor** effective against influenza A and B, but it is administered via inhalation. - While effective, **oseltamivir** is generally preferred for chemoprophylaxis due to its oral administration, making it more convenient for widespread use [2].

Q: Which one of the following is the antibiotic of choice for the prevention of Rheumatic Heart Disease?

Benzathine Benzyl Penicillin. ***Benzathine Benzyl Penicillin*** - It is the antibiotic of choice for the **prevention of Rheumatic Heart Disease (RHD)** due to its **long-acting nature** and effectiveness against **Group A Streptococcus (GAS)**. - A single intramuscular injection provides **sustained therapeutic levels** for several weeks, crucial for preventing recurrent GAS infections that lead to RHD. *Doxycycline* - Not effective for **primary prevention of Rheumatic Fever** or RHD as it is not a first-line agent against **Group A Streptococcus**. - Mainly used for **atypical bacteria** and certain parasitic infections. *Procaine Penicillin* - It has a shorter duration of action compared to **benzathine penicillin**. - Requires more frequent injections, making it less suitable for **long-term prophylaxis** in RHD prevention. *Ciprofloxacin* - This is a **fluoroquinolone antibiotic** and is not the antibiotic of choice for **Group A Streptococcus infections**. - Its use in this context could contribute to **antibiotic resistance** without providing effective prophylaxis for RHD.

Q: All of the following are true about Bedaquiline (BDQ) EXCEPT:

It is a bacteriostatic drug. ***It is a bacteriostatic drug*** - **Bedaquiline (BDQ)** is a novel anti-tuberculosis drug that is **bactericidal** against *Mycobacterium tuberculosis*, meaning it kills the bacteria rather than just inhibiting their growth. - Its bactericidal action is crucial for treating multi-drug resistant (MDR) and extensively drug-resistant (XDR) tuberculosis. *It has extended half-life* - **Bedaquiline** has a very **long terminal elimination half-life**, which can extend up to several months. - This extended half-life allows for less frequent dosing schedules (e.g., once daily or thrice weekly after an initial loading phase). *It specifically targets mycobacterial ATP synthase* - **Bedaquiline** specifically inhibits **mycobacterial ATP synthase**, an enzyme essential for energy production in *Mycobacterium tuberculosis* [1]. - This unique mechanism of action contributes to its effectiveness against traditional drug-resistant strains [1]. *It has high volume of tissue distribution* - **Bedaquiline** is highly lipophilic and extensively distributed into tissues, resulting in a **large volume of distribution**. - This extensive tissue distribution contributes to its long half-life and allows it to reach therapeutic concentrations within the infection sites.

Question 1

Which one of the following groups of drugs is ineffective against gram positive bacteria?

Accepted Answer

Monobactams

Answer

Glycopeptides

Answer

Fluoroquinolones

Answer

First generation cephalosporins

Question 2

For the treatment of kala-azar, the daily dose of miltefosine in a 3-year-old child who weighs 15 kg is

Accepted Answer

40 mg

Answer

20 mg

Answer

10 mg

Answer

30 mg

Question 3

Which of the following statements is true about antibiotic therapy?

Accepted Answer

It has its greatest effect on multiplying organisms

Answer

It enhances the intracellular killing of organisms by phagocytes

Answer

It facilitates killing of organisms by activation of complements

Answer

It enhances the uptake of organisms by phagocytes

Question 4

Consider the following drugs :
1. Rifampicin
2. Dapsone
3. Clofazimine
4. Minocycline
Which of the above drugs are used in the standard treatment of pauci-bacillary leprosy in adults?

Accepted Answer

1 and 2 only

Answer

1, 2 and 3

Answer

1 and 4

Answer

2, 3 and 4

Question 5

In a case of paucibacillary leprosy, treatment is considered adequate if the patient has received the six monthly doses of combined therapy within:

Accepted Answer

9 months

Answer

12 months

Answer

6 months

Answer

15 months

Question 6

Which of the following drugs should be avoided in the first-line ART regimens because of its well recognized metabolic toxicities ?

Accepted Answer

Stavudine (d4T)

Answer

Tenofovir (TDF)

Answer

Zidovudine (AZT)

Answer

Lamivudine (3TC)

Question 7

All of the following drugs are effective for treatment of hookworm infection in single dose EXCEPT:

Accepted Answer

Piperazine

Answer

Albendazole

Answer

Levamisole

Answer

Pyrantel

Question 8

The drug of choice for chemoprophylaxis to health care personnel and close contacts of suspected or confirmed case of pandemic influenza A (H1N1) is:

Accepted Answer

Oseltamivir

Answer

Ribavirin

Answer

Amantadine

Answer

Zanamivir

Question 9

Which one of the following is the antibiotic of choice for the prevention of Rheumatic Heart Disease?

Accepted Answer

Benzathine Benzyl Penicillin

Answer

Doxycycline

Answer

Procaine Penicillin

Answer

Ciprofloxacin

Question 10

All of the following are true about Bedaquiline (BDQ) EXCEPT:

Accepted Answer

It is a bacteriostatic drug

Answer

It has extended half life

Answer

It specifically targets mycobacterial ATP synthase

Answer

It has high volume of tissue distribution

Antimicrobial Agents — MCQs

Antimicrobial Agents — MCQs

On this page

Practice by Chapter

Want unlimited practice?